Previous 10 | Next 10 |
The oncology market covers every area of cancer care, from diagnosis to treatment, and is one of the biggest sectors in the life science space. Cancer is the second leading cause of death worldwide, after cardiovascular diseases. Biotechnology and pharmaceutical companie...
As COVID-19 decelerates its growth, Guardant has failed to generate sizable capital gains despite the recent FDA signoff. With vaccine hopes rising, the consensus revenue estimates look overly modest and the discount in the trading multiple compared to the past seems unwarranted. ...
In its recent 13F filing, Coatue Management reported a significant growth in total fund portfolio value to $19.05B from $11.37B in the earlier quarter.Notable buys: Best Buy (BBY), Expedia (EXPE), American Eagle Outfitters (AEO), L Brands (LB) and Gap (GPS).Q3 portfolio activity included nume...
Multiple companies are working on next-gen blood biopsies tech to detect cancer. The potential market size is big according to most estimates and analysts. Mergers and acquisitions seem to suggest that the era of liquid biopsies has arrived. The frontrunners highlighted in the...
Guardant Health (GH) has priced its offering of $1B of 0% convertible senior unsecured notes due November 15, 2027 in a private offering.Initial purchasers granted an option to purchase up to an additional $150M of notes.Closing date is November 19.The company estimates net proceeds of ~...
Guardant Health, Inc. (Nasdaq: GH) today announced the pricing of its offering of $1,000,000,000 aggregate principal amount of 0% convertible senior notes due 2027 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securit...
Despite the roaring bull market on Monday, shares of cancer diagnostics specialist Guardant Health (NASDAQ: GH) fell dramatically. There was little mystery as to why this occurred. The drop is the whipsaw investor reaction to Guardant's announcement that morning that it plans to...
Guardant Health, Inc. (Nasdaq: GH) today announced its intention to offer, subject to market and other conditions, $1,000,000,000 aggregate principal amount of convertible senior notes due 2027 (the “notes”) in a private offering to qualified institutional buyers pursuant ...
Throughout the turmoil of the pandemic, Quidel Corporation (NASDAQ: QDEL) and Guardant Health (NASDAQ: GH) are continuing to innovate with their medical testing and diagnostic products. Both companies are experiencing rapid revenue growth, and neither is being held back by c...
Image source: The Motley Fool. Guardant Health Inc (NASDAQ: GH) Q3 2020 Earnings Call Nov 6, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: Guardant Health Inc (GH) Q3 2020 Earnings Call Transcript
News, Short Squeeze, Breakout and More Instantly...
Shield is first blood test approved by FDA as a primary screening option for colorectal cancer and that meets performance requirements for Medicare coverage Blood test offers easy, convenient and pleasant screening option with potential for improving colorectal cancer screening rates ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Ti...
Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity Upgraded test covered ...